Definium’s LSD formula produces ‘best data ever seen’ in a pivotal depression trial, CEO says
Definium Therapeutics' LSD-based depression treatment shows promising results in a pivotal trial, driving stock surge
Evidence dossier
Intelligence passport
Measured timeline
- Detected The first matching coverage entered the Archynetys cluster.
- Latest coverage observed Most recent article currently attached to this story cluster.
- Peak measured velocity The recorded velocity reached 8.
- Evidence threshold reached The story had enough independent coverage for an explanatory brief.
- Outcome review added Archynetys revisited the signal after coverage cooled.
Source diversity sample: BioSpace · Yahoo Finance · Psychedelic Alpha · WSJ · Business Wire · FirstWord Pharma · statnews.com · Reuters.
How this dossier is built: methodology · AI policy · corrections.
📍 Aftermath
Definium Therapeutics announced positive topline results from its Phase 3 Emerge study of the DT120 orally disintegrating tablet for major depressive disorder. The LSD-based therapy demonstrated strong antidepressant effects and profound efficacy, which led to a surge in the company's stock price.
Epilogue added 65d ago, after coverage quieted.
How fast it spread
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
Where it stands
- Velocity & Diffusion: Coverage exploded across 9 distinct news outlets with 11 published articles, achieving a live velocity of 8.
- Primary Driver: Definium Therapeutics' LSD-based depression treatment shows promising results in a pivotal trial, driving stock surge
- Predictive Outlook: Archynetys algorithmic models forecast this story will fade from trending status over the next 24 hours.
- Source Integrity: Verified strictly against primary headline reporting under zero-hallucination protocols.
Definium Therapeutics has reported positive results from a Phase 3 trial of its LSD-based depression treatment, DT120. The company's CEO described the data as the 'best ever seen' in such a trial.
Coverage from outlets including BioSpace, Yahoo Finance, and Reuters emphasizes the strong efficacy of the drug in treating major depressive disorder. Business Wire reports that Definium will discuss the topline results from the Phase 3 Emerge study.
The next steps involve further analysis of the trial data and potential regulatory submissions. Coverage does not yet specify the timeline for these processes.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 78d ago.
Sources (11)
- Definium’s LSD-based therapy elicits ‘profound’ efficacy in Phase 3 depression trial BioSpace · 80d ago
- Definium Therapeutics (DFTX) Hits New High on Impressive Drug Candidate Trial Yahoo Finance · 80d ago
- Breaking: Definium Lands Positive Phase 3, LSD Candidate Shows Strong Antidepressant Effect Psychedelic Alpha · 80d ago
- 🔎 Under the Radar: Definium Shares Propelled by Strong Psychedelic Results WSJ · 80d ago
- Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder Business Wire · 80d ago
- Definium's LSD-based drug scores win in key major depressive disorder study FirstWord Pharma · 80d ago
- Definium LSD therapy helped patients with major depression in late-stage trial statnews.com · 80d ago
- DFTX Stock Rallies Ahead Of High-Stakes Phase 3 Depression Drug Trial Results Yahoo Finance · 80d ago
- Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026 Business Wire · 80d ago
- Definium's LSD-based depression pill delivers strong late-stage results, shares surge Reuters · 80d ago
- Definium’s LSD formula produces ‘best data ever seen’ in a pivotal depression trial, CEO says Fierce Biotech · 80d ago
Answered
What is the name of Definium's LSD-based depression treatment?
The treatment is called DT120.
Which phase of trial has DT120 completed?
DT120 has completed a Phase 3 trial.
What is the stock ticker for Definium Therapeutics?
The stock ticker for Definium Therapeutics is DFTX.
Topics
Related trends
'Fall From Grace'
Ultragenyx's Angelman trial failure triggers drastic cost-cutting measures
Depression-Treating Magnetic Coils Have Arrived to Humboldt County
Magnetic brain stimulation for depression is now available in Humboldt County.
Arthritis drug may help regrow up to 80% of hair in alopecia areata
A drug used to treat arthritis is showing promise in treating alopecia areata, a condition that causes hair loss.
A New Use for GLP-1s? Amylyx Pharma Catapults To 3-Year High
Amylyx Pharmaceuticals' stock surges after a GLP-1 antagonist drug shows promise in a new application.
Cullinan tees up J&J fight—and $100M payday—as Taiho-partnered drug hits phase 3 cancer goal
Cullinan and Taiho's lung cancer drug has passed a major clinical trial, setting up a potential challenge to Johnson & Johnson's market-leading treatment.
Definium hits another phase 3 homerun with psychedelic ‘sea change’ for anxiety
Definium Therapeutics' LSD therapy shows promise in easing anxiety in a late-stage trial.
Open prediction lab
Can you beat the machine?
Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.
📬 The daily trend digest
The world's top trends, once a day. No spam, one-click unsubscribe.